R. Dent

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

Tomasz Byrski, Tomasz Huzarski, R. Dent et al. · Breast Cancer Research and Treatment · 2014 · 269 citations

Medicine, Oncology, Pharmacology +14

KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)

Javier Cortés, Oleg Lipatov, S. Im et al. · Annals of Oncology · 2019 · 132 citations

Medicine, Oncology, Pharmacology +16

Survival of women with inflammatory breast cancer: a large population-based study

Shaheenah Dawood, Xiudong Lei, R. Dent et al. · Annals of Oncology · 2014 · 63 citations · Full text

Medicine, Gynecology, Oncology +9

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, Fabrice André, Anthony Gonçalvès et al. · Annals of Oncology · 2024 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial

R. Dent, Zhi-Ming Shao, P. Schmid et al. · Annals of Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +15